Search

everythinglearnresearchcommunity

for

Search:↓

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

Targeting specific biomarkers and immune signals is more effective and safer for treating inflammatory skin diseases.

Intestinal intraepithelial lymphocytes are crucial for gut immunity and maintaining the mucosal barrier.

Machine learning can help identify biomarkers for personalized Pemphigus vulgaris treatment.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Immune-epithelial interactions are crucial for tissue repair, but unchecked can cause diseases.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

Pemphigus vulgaris involves specific immune cells and B cells that produce antibodies causing skin blisters.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Microneedles offer a promising, painless, and efficient way to deliver vaccines and therapies directly to the skin.

TNF-alpha inhibitors can cause various immune-related skin issues.

Melanocytes may trigger the immune response in alopecia areata, affecting hair regrowth.

IL-13 protein is much higher in the skin of atopic dermatitis patients than in healthy skin.

Immune cells help keep skin healthy and repair it, but imbalance can cause disease.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Rats can develop an immune response to prion protein peptides, but it may cause severe skin issues in older rats.

An isolated episcleral plasmacytoma can mimic episcleritis, making diagnosis challenging.

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

A patient's skin rash did not affect the area where a previous viral rash was healing, suggesting a rare immune response.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Skin side effects from melanoma immunotherapy are common and may indicate better survival.